{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T18:18:23Z","timestamp":1725473903876},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1016\/j.ijantimicag.2003.09.008","type":"journal-article","created":{"date-parts":[[2004,3,9]],"date-time":"2004-03-09T08:52:41Z","timestamp":1078822361000},"page":"83-87","source":"Crossref","is-referenced-by-count":4,"special_numbering":"S1","title":["Single-drug or combined antibacterial therapy in the treatment of patients with chronic prostatitis and Chlamydia trachomatis?"],"prefix":"10.1016","volume":"23","author":[{"given":"V","family":"Smelov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Gorelov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Smelova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Krylova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2003.09.008_BIB1","unstructured":"Naber KG, Bergman B, Bishop MC, Bjerklund-Johansen TE, Botto H, Lobel B, et al. Prostatitis, epididymitis and orchitis. In: EAU Guidelines on Urinary and Male Genital Tract Infection. Arhnem: Drukkerij Gelderland bv; 2001."},{"key":"10.1016\/j.ijantimicag.2003.09.008_BIB2","doi-asserted-by":"crossref","unstructured":"Nickel JC. Prostatitis: evolving management strategies. In: Carson CC, guest editor. The Urologic Clinics of North America. W.B. Saunders Company: London; 1999.","DOI":"10.1016\/S0094-0143(05)70215-9"},{"key":"10.1016\/j.ijantimicag.2003.09.008_BIB3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1159\/000019784","article-title":"The role of antibiotics in the treatment of chronic prostatitis: a consensus statement","volume":"34","author":"Bjerklund Johansen","year":"1998","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ijantimicag.2003.09.008_BIB4","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1093\/infdis\/162.6.1309","article-title":"Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics","volume":"162","author":"Jones","year":"1990","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijantimicag.2003.09.008_BIB5","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1086\/315372","article-title":"Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure","volume":"181","author":"Somani","year":"2000","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijantimicag.2003.09.008_BIB6","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/00007435-199808000-00005","article-title":"Comparative in vitro susceptibility of a tetracycline-resistant Chlamydia trachomatis strain isolated in Toulouse (France)","volume":"25","author":"Lefevre","year":"1998","journal-title":"Sex Transm. Dis."},{"key":"10.1016\/j.ijantimicag.2003.09.008_BIB7","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1128\/AAC.39.3.760","article-title":"Susceptibilities of Chlamydia trachomatis isolates causing uncomplicated female genital tract infections and pelvic inflammatory disease","volume":"39","author":"Rice","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijantimicag.2003.09.008_BIB8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000007192","article-title":"minimum inhibitory and minimal lethal concentration against Chlamydia trachomatis dependent on the time of addition and the duration of the presence of antibiotics","volume":"45","author":"Notomi","year":"1999","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2003.09.008_BIB9","first-page":"313","article-title":"In vitro evaluation of activities of azithromycin, clarithromycin and sparfloxacin against Chlamydia trachomatis","volume":"41","author":"Lefevre","year":"1993","journal-title":"Pathol. Biol. (Paris)"},{"key":"10.1016\/j.ijantimicag.2003.09.008_BIB10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0732-8893(01)00221-8","article-title":"In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines","volume":"39","author":"Samra","year":"2001","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ijantimicag.2003.09.008_BIB11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1159\/000019784","article-title":"The role of antibiotics in the treatment of chronic prostatitis: a consensus statement","volume":"34","author":"Bjerklund Johansen","year":"1998","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ijantimicag.2003.09.008_BIB12","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1128\/AAC.45.11.3001-3008.2001","article-title":"Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro","volume":"45","author":"Dreses-Werringloer","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijantimicag.2003.09.008_BIB13","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1128\/AAC.42.10.2474","article-title":"Sequencing of gyrase and topoisomerase IV quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained in vitro","volume":"42","author":"Dessus-Babus","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijantimicag.2003.09.008_BIB14","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1128\/AAC.44.12.3288-3297.2000","article-title":"Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro","volume":"44","author":"Dreses-Werringloer","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijantimicag.2003.09.008_BIB15","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jac\/dkf031","article-title":"Serial passage of Chlamydia spp. in sub-inhibitory fluoroquinolone concentrations","volume":"49","author":"Morrissey","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijantimicag.2003.09.008_BIB16","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1128\/AAC.43.6.1491","article-title":"Effect of azithromycin plus rifampicin versus that of azithromycin alone on the eradication of Chlamydia pneumoniae from lung tissue in experimental pneumonitis","volume":"43","author":"Wolf","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijantimicag.2003.09.008_BIB17","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1128\/AAC.44.6.1761-1764.2000","article-title":"Effect of azithromycin plus rifampicin versus amoxicillin alone in the chronic course Chlamydia pneumoniae pneumonitis in mice","volume":"44","author":"Bin","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijantimicag.2003.09.008_BIB18","unstructured":"Smelov VE. Method of urogenital chlamydiosis treatment (Patent for invention RU2173987). Bulletin N27 of the Russian Agency for Patents and Trade Marks. Moscow: Federal Institute of Industrial Property; 27 September 2001."},{"key":"10.1016\/j.ijantimicag.2003.09.008_BIB19","unstructured":"Center for Disease Control. Sexually Transmitted Diseases Treatment Guidelines, vol. 51(RR-6). 2002. p. 32\u20136."},{"key":"10.1016\/j.ijantimicag.2003.09.008_BIB20","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/315778","article-title":"Evidence for long-term cervical persistence of Chlamydia trachomatis by omp1 genotyping","volume":"182","author":"Dean","year":"2000","journal-title":"J. Infect. Dis."}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857903003479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857903003479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T11:41:52Z","timestamp":1585654912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857903003479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":20,"alternative-id":["S0924857903003479"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2003.09.008","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}